Bivalent TRK Degradation Compounds for Mutant and Fusion Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases associated with tropomyosin receptor kinase (TRK) are limited in efficacy and specificity, particularly in targeting TRK-related mutations and fusions.
Innovation Solution
Development of bivalent compounds that act as TRK ligands conjugated to degradation tags, enabling targeted degradation of TRK proteins through ubiquitin ligase-mediated pathways, utilizing specific E3 ligases like cereblon or VHL to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional TRK treatments are used, then treatment coverage is provided, but efficacy and specificity are limited
Solution Approach 1:
The compound is divided into two functional segments: a TRK ligand portion that binds to TRK proteins and a degradation tag portion that recruits E3 ligases. This segmentation allows each portion to be optimized independently for its specific function, thereby improving overall therapeutic efficacy and specificity against TRK-related mutations and fusions.
Solution Approach 2:
The patent introduces E3 ligases (such as cereblon or VHL) as intermediary proteins that mediate the degradation process. The degradation tag portion of the compound interacts with these E3 ligases to facilitate TRK protein degradation, enhancing the therapeutic effect while maintaining specificity for TRK-related diseases.
2Reliability
If TRK ligands are used, then TRK binding is achieved, but protein degradation is insufficient
Solution Approach 1:
The patent merges two functions into a single compound molecule: TRK binding (via the ligand portion) and protein degradation induction (via the degradation tag portion). This combination allows the compound to simultaneously achieve accurate TRK targeting and effective protein degradation, resolving the contradiction between binding accuracy and degradation productivity.
Solution Approach 2:
The compound functions as a composite molecular system integrating different functional moieties: a TRK ligand segment for binding and a degradation tag segment for recruiting E3 ligases. This composite structure enables coordinated action of both binding and degradation functions, enhancing overall therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bivalent compounds effectively target and degrade TRK proteins, including mutants and fusions, offering improved therapeutic outcomes by enhancing specificity and efficacy against TRK-related diseases.
Implementation Method 1
enabling targeted degradation of TRK proteins through ubiquitin ligase-mediated pathways
Implementation Method 2
utilizing specific E3 ligases like cereblon or VHL to enhance therapeutic efficacy
Data Source
AI summary
This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.